DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk test at all three of its greater Dayton, Ohio locations. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer. More than 80 percent of women who develop breast cancer, have little or no family history of the disease.1 "In the Dayton area, the number one cancer diagnosis is breast cancer, followed by prostate and colon cancer," said Dr. Caroline Peterson, DO, Contemporary Obstetrics & Gynecology. "Because of this, we've been looking for a test like BREVAGen to help identify and more aggressively monitor women who are at higher risk of developing the disease." Contemporary Obstetrics & Gynecology is the first practice in the Dayton area to fully adopt BREVAGen into their practice. They began administering BREVAGen to women in late July of this year and since then, 243 women over the age of 35 have been tested. Thus far, results have shown that 23 percent have been identified as high risk for developing breast cancer and 77 percent at low risk for developing the disease. The physicians at Contemporary Obstetrics & Gynecology have created a clinical protocol to enact once a patient is identified as high risk. The protocol includes specific steps and a quick timeline for a team providers and the patient to follow to make sure the patient has the appropriate care to keep her healthy. Dr. Peterson added, "With BREVAGen, we can get ahead of each woman's personal risk and do something proactive about it for cancer detection and prevention." BREVAGen, which is a simple cheek swab test, is a clinically validated predictive risk test that more accurately identifies a woman's unique risk of developing sporadic, estrogen-positive breast cancer. BREVAGen examines a woman's clinical risk factors, such as their lifetime exposure to estrogen, combined with scientifically validated markers to determine each patient's personalized five-year and lifetime risk of developing breast cancer.2 BREVAGen is supplied by Phenogen Sciences, a subsidiary of Genetic Technologies Limited (Nasdaq:GENE). For more information about BREVAGen at Contemporary Obstetrics & Gynecology, contact the office at (937) 433-4325. How BREVAGen Works
- Approximately one in eight women will get breast cancer5
- 70% to 80% of those who get breast cancer do not have familial risk indicators3
- Risk of invasive vs. non-invasive breast cancer is approximately four times greater in women age 40-646
- Approximately 75% of all breast cancer is estrogen-positive and, if detected early, can be effectively treated with five-year survival rates of over 95%
- Approximately 207,000 new cases diagnosed each year5
- Of the 207,000 new cases, about 54,000 are non-invasive forms of breast cancer that have been diagnosed early5
- Approximately 40,000 deaths related to breast cancer in women, annually5
- Non-invasive, easy-to-use predictive risk assessment test
- The first genetic risk prediction test to have been validated in a large-scale, peer-reviewed, case-controlled study2
- Recent studies demonstrate that 64% of women who have above average risk of prolonged estrogen exposure were either reclassified above the guidelines for high risk management or below the general population risk when compared to clinical risk factors alone2
- Supports existing industry guidelines for the prevention of estrogen-positive breast cancer3,4
- Video One: http://www.youtube.com/watch?v=-em2pNeOMNs&feature=plcp
- Video Two: http://www.youtube.com/watch?v=BSExN7mNlzA&feature=plcp
- Breast Cancer: Early Detection. American Cancer Society. Accessed May 13, 2013 at http://www.cancer.org/acs/groups/cid/documents/webcontent/003165-pdf.pdf.
- Mealiffe M, Stokowski RP, Rhees, BK, et al. J Nat Cancer Inst. 2010;102(21):1618-1627.
- Saslow D, Boetes C, Burke W, et al. CA Cancer J Clin. 2007;57(2):75-89.
- Visvanathan K, Chlebowski RT, Hurley P, et al. J Clin Oncol. 2009;27(19):3235-3258.
- Breast Cancer Overview. American Cancer Society. Accessed 3/14/12 at http://www.cancer.org/cancer/breastcancer/overviewguide/index
- DeSantis C, Siegel R, Bandi P, Jemal A. CA: A Cancer Journal For Clinicians. 2011;61: 409-418
CONTACT: Andrea Preston Kovak-Likly Communications (203) 762-8833 or APreston@KLCpr.com